NDNazlı Demirkıran

Nazlı Demirkıran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nazlı Demirkıran has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Resveratrol Stabilizes Cytosolic ß-Catenin Through The Activation of The Thermogenic Cascade

    by Bengüsu Aydın, Nazlı Demirkıran, Sude Günaydın, Hakki Ogün Sercan

    Purpose: Resveratrol is a polyphenolic compound that has been shown to stimulate fatty acid oxidation and increase the expression of genes associated with thermogenic processes. Therefore, it is important to investigate the effects of resveratrol beyond intracellular thermogenic pathways to determine side effects at the cellular level. The aim of this study was to evaluate the effect of resveratrol on intracellular ß-catenin, in addition to its thermogenic effect. Materials and methods: The effect of resveratrol on thermogenic genes such as SIRT1 gene, UCP1, PGC1α, PRDM16 and ß-catenin gene expression levels was analyzed by RT-PCR. The cytosolic ß-catenin level analyzed by western-blot. Results: The effect of resveratrol on thermogenic genes such as SIRT1 gene, UCP1, PGC1α, PRDM16 and ß-catenin gene expression levels was analyzed by RT-PCR. The cytosolic ß-catenin level analyzed by western-blot. We found that the expression levels of UCP1, PPARγ, PRDM16 were increased by SIRT1 protein activated by resveratrol, but it had no effect on ß-catenin mRNA expression. While ß-catenin did not change at the mRNA level, we found that ß-catenin increased at the protein level in the cell independently of the canonical Wnt pathway. Conclusion: Our results suggest that resveratrol, which is widely used as a supplement, may also act on different signaling pathways in the cell.


  • Open Access

    Cisplatin Impact on Kasumi-1 Leukemia: Gene Expression and DNA Damage

    by Yavuz Dodurga, Mücahit Seçme, Levent Elmas, Nazlı Demirkıran, Sevda Sağ, Ulviye Adamcı, Zeliha Akdağ

    Purpose: Leukemia is a type of cancer caused by the uncontrolled proliferation of blood cells. The purpose of this study was to investigate the effects of cisplatin (CIS), a chemotherapeutic agent used in the treatment of leukemia, on the Kasumi-1 leukemia cell line. Materials and methods: The study measured the effect of CIS on Kasumi-1 cells by calculating IC50 values for cell viability. The mRNA expression levels of apoptosis and cell cycle-related genes were then assessed using Real-Time PCR. In addition, the effects of CIS on DNA damage were investigated using the comet assay. Results: Significant changes in apoptosis and cell cycle-related genes were observed in CIS-treated groups. These included alterations in the mRNA levels of p53, BCL-2, CHECK 1, CDC25C, CDK 6, URG4/URGCP, GADD45A, CCND1, GADD45G, and ATM genes. Comet analysis confirmed CIS's effects on DNA damage. Conclusion: This study aimed to better understand how CIS affects genetic mechanisms in leukemia cells and provide new insights into leukemia treatment. The findings will help us better understand the role of CIS in leukemia treatment and will serve as a valuable reference for future research.


  • Open Access

    Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells

    by Yavuz Dodurga, Levent Elmas, Mücahit Seçme, Nazlı Demirkıran, Çığır Biray Avcı, Gülseren Bağcı, Sevda Sağ, Lale Şatıroğlu Tufan

    Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.